MedTrace Logo

Registry to Measure the Impact of Adding Genomic Testing

NCT02454595 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2017-09-05

No results posted yet for this study

Summary

This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer. Physicians will complete a series of questionnaires. Biopsy tissue will be tested using the Prolaris® genomic test and a relative cancer aggressiveness score will be shared with the physician and the patient.

Conditions

Interventions

BEHAVIORAL

Registry

Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).

Sponsors & Collaborators

  • Intermountain Health Care, Inc.

    collaborator OTHER

  • Myriad Genetic Laboratories, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Wenstrup, MD · Myriad Genetic Laboratories, Inc.

Eligibility

Min Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-07-03
Completion
2017-07-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02454595 on ClinicalTrials.gov